REFERENCES
- Babiuk L. A., Tikoo S. K. Adenoviruses as vectors for delivering vaccines to mucosal surfaces. J. Biotechnol. 2000; 83: 105–113, [PUBMED], [INFOTRIEVE]
- Baldridge J. R., Yorgensen Y., Ward J. R., et al. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 2000; 18: 2416–2425, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Beagley K. W., Husband A. J. Intraepithelial lymphocytes: Origins, distribution, and function. Crit. Rev. Immunol. 1998; 18: 237–254, [PUBMED], [INFOTRIEVE], [CSA]
- Bender B. S., Rowe C. A., Taylor S. F., et al. Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J. Virol. 1996; 70: 6418–6424, [PUBMED], [INFOTRIEVE], [CSA]
- Black S., Shinefield H., Fireman B., et al. Efficacy, safety and Immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J. 2000; 19: 187–195, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Brandtzaeg P., Farstad I. N., Haralssen G., et al. Cellular and molecular mechanisms for induction of mucosal immunity. Dev. Biol. Stand. 2000; 92: 93–108, [CSA]
- Coffman R. L., Seymour B. W., Lebman, et al. The role of helper T cell products in mouse B cell differentiation and isotype regulation. Immunol. Rev. 1988; 102: 5–28, [PUBMED], [INFOTRIEVE]
- Cruz J. R., Gil L., Cano F., et al. Breast milk anti-Escherichia coli heal- labile toxin IgA antibodies protect against toxin-induced infantile diarrhea. Acta Paediatr. Scand. 1988; 77: 658–662, [PUBMED], [INFOTRIEVE]
- Czerkinsky C., Holmgren J. The mucosal immune system and prospects for anti-infectious and anti-inflammatory vaccine. Immunologist 1995; 3: 97–103
- Davis H. L., Weeranta L. R., Waldschmidt T. J., et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 1998; 160: 870–876, [PUBMED], [INFOTRIEVE]
- De Hann L., Holtrop M., Verweij W. R., et al. Mucosal immunogenicity and adjuvant activity of the recombinant A subunit of the Escherichia coli heat-labile enterotoxin. Immunology 1999; 97: 706–713, [CROSSREF]
- Ey P. L., Russell-Jones G. L., Jenkin C. R. Isotypes of mouse IgG-I. Evidence for “non-complement-fixing” IgG1 antibodies and characterization of their capacity to interfere with IgG2 sensitization of target red blood cells for lysis by complement. Mol. Immunol. 1980; 17: 699–710, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Freytag L. C., Clements J. D. Bacterial toxins as mucosal adjuvants. Curr. Top. Microbiol. Immunol. 1999; 236: 215–236, [PUBMED], [INFOTRIEVE], [CSA]
- Fujihashi K., Koga R., van Ginkel F. W., et al. A dilemma for mucosal vaccination: Efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 2002; 20(19–20)2431–2438, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gay N., Ramsay M., Waight P. Rotavirus vaccination and intussusception. Lancet 1999; 354: 956, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Giebink G. S. Preventing pneumococcal diseases in children: Recommendation for using pneumococcal vaccines. Pediatr. Infect. Dis. J. 1985; 4: 343–348
- Giebink G. S. The microbiology of otitis media. Pediatr. Infect. Dis. J. 1989; 8: 18–20
- Greenspan N. S., Cooper L. J.N. Intermolecualr cooperativity: A clue to why mice have IgG3?. Immunol. Today 1992; 13: 164–168, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gruber W. C. The role of live influenza vaccines in children. Vaccine 2002; 20: S66–S73, (Suppl 2)[PUBMED], [INFOTRIEVE], [CROSSREF]
- Haan L., Verweij W. R., Holtrop M., et al. Nasal or intramuscular immunization of mice with influenzae subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity. Vaccine 2001; 19: 2898–2907, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hemmi H., Takeuchi O., Kawai T., et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740–745, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Horner A. A., Raz E. Immunostimulatory sequence oligodeoxynucleotide: A novel mucosal adjuvant. Clin. Immunol. 2000; 95: S19–S29, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hou Y., Hu W. G., Hirano T., et al. A new intra-NALT route elicits mucosal and systemic immunity against Moraxella catarrhalis in a mouse challenge model. Vaccine 2002; 20: 2375–2381, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jakobsen H., Jonsdottir I. Mucosal vaccination against encapsulated respiratory bacteria—New potentials for conjugate vaccines?. Scand. J. Immunol. 2003; 58(2)119–139, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Janeway C. A., Jr., Mcdzhitov R. Introduction: The role of innate immunity in the adaptive immune response. Semin. Immunol. 1998; 10(5)349–350, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Katial R. K., Brandt B. L., Moran E. E., et al. Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine. Infect. Immun. 2002; 70(2)702–707, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kelsall B. L., Strober W. Distinct populations of dendritic cells are present in the subepithelial dome and T cell regions of the murine Peyer's patch. J. Exptl. Med. 1996; 183: 237–247, [CROSSREF], [CSA]
- Krieg A. M., Hartmann G., Yi A. K. Mechanism of action of CpG DNA. Curr. Top. Microbiol. Immunol. 2000; 247: 1–21
- Krieg A. M., Yi A. K., Matson T. J., et al. CpG motifs in bacterial DNA trigger direct B cell activation. Nature 1995; 374: 546–549, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Lee C. J. Advances in pneumococcal vaccines. Infect. Med. 1999; 16(9)596–612
- Lee C. J., Lee L. H., Frasch C. E. Protective immunity of pneumococcal glycoconjugates. Crit. Rev. Microbiol. 2003; 29(4)1–17, [CSA]
- Lee C. J., Wang T. R., Frasch C. E. Immunogenicity in mice of pneumococcal glycoconjugate vaccines using pneumococcal protein carriers. Vaccine 2001; 19: 3216–3225, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lycke N. The mechanism of cholera toxin adjuvanticity. Res. Immunol. 1997; 148: 504–520, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lycke N., Tsuji T., Holmgren J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 1992; 22: 2277–2281, [PUBMED], [INFOTRIEVE], [CSA]
- McCluskie M. J., Davis H. L. CpG DNA as mucosal adjuvant. Vaccine 1999; 18: 231–237, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- McCluskie M. J., Weeratna R. D., Davis H. L. Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution. Mol. Med. 2000; 6: 867–877, [PUBMED], [INFOTRIEVE]
- McCluskie M. J., Weeratna R. D., Payette P. J., et al. The potential of CpG oligodeoxynucleotides as mucosal adjuvants. Crit. Rev. Immunol. 2001; 21: 103–120, [PUBMED], [INFOTRIEVE], [CSA]
- McKenzie B. S., Brady J. L., Lew A. M. Mucosal immunity: Overcoming the barrier for induction of proximal responses. Immunol. Res. 2004; 30(1)35–71, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- McNeal M. M., Rae M. N., Conner M. E., et al. Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21. Virology 1998; 243: 158–166, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mendelman P. M., Cordova J., Cho I. Safety, efficacy and effectiveness of the influenza virus vaccine, trivalent, types A and B, live, cold-adapted (CAIV-T) in healthy children and healthy adults. Vaccine 2001; 19: 2221–2226, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mowat A. M., Donachie A. M., Jagewall S., et al. CTA1-DD-immune stimulating complexes: A novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen. J. Immunol. 2001; 167: 3398–3405, [PUBMED], [INFOTRIEVE]
- Olszewska W., Partidos C. D., Steward M. W. Antipeptide antibody responses following intranasal immunization: Effectiveness of mucosal adjuvants. Infect. Immun. 2000; 68: 4923–4929, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Owen R. L. Uptake and transport of intestinal macromolecules and microorganisms by M cells in Peyer's patches: A personal and historical perspective. Semin. Immunol. 1999; 11: 157–163, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Pankow W., von Wichert P. M cell in the immune system of the lung. Respiration 1988; 54: 209–219, [PUBMED], [INFOTRIEVE]
- Pizza M., Giuliani M. M., Fontana M. R., et al. Mucosal vaccines: Non-toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 2001; 19: 2534–2541, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rappuoli R., Douce G., Dougan G., et al. Genetic detoxification of bacterial toxins: A new approach to vaccine development. Int. Arch. Allergy Immunol. 1995; 108: 327–333, [PUBMED], [INFOTRIEVE], [CSA]
- Robbins J. B., Schneerson R., Szu S. C. Perspective hypothesis: Serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 1995; 171: 1387–1398, [PUBMED], [INFOTRIEVE]
- Roos A., Bouwman L. H., van Gijlswijk-Janssen D. J., et al. Human IgA activates the complement system via the mannan-binding lectin pathway. I. Immunol. 2001; 167: 2861–2868
- Russell M. W., Mansa B. Complement-fixing properties of human IgA antibodies. Alternative pathway complement activation by plastic-bound, but not specific antigen-bound, IgA. Scand. J. Immunol. 1989; 30: 175–183, [PUBMED], [INFOTRIEVE]
- Sasaki S., Hamajima K., Fukushima J., et al. Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a DNA-monophospharyl lipid A adjuvant vaccine. Infect. Immun. 1998; 66: 823–826, [PUBMED], [INFOTRIEVE], [CSA]
- Sasaki S., Sumino K., Mamajima K., et al. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes. J. Virol. 1998; 72: 4931–4939, [PUBMED], [INFOTRIEVE], [CSA]
- Seong S. Y., Cho N. H., Kwon I. C., et al. Protective immunity of microsphere-based mucosal vaccines against lethal intranasal challenge with Streptococcus pneumoniae. Infect. Immun. 1999; 67: 3587–3592, [PUBMED], [INFOTRIEVE], [CSA]
- Simmons C. P., Ghaem-Magami M., Petrovska L., et al. Immunomodulation using bacterial enterotoxins. Scand. J. Immunol. 2001; 53: 218–226, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Singh M., O'Hagan D. Advances in vaccine adjuvants. Nat. Biotechnol. 1999; 17: 1075–1081, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sisk J. E., Moskowitz A. J., Whang W., et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997; 278: 1333–1339, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Sonoda E., Matsumoto R., Hitoshi Y., et al. Transforming growth factor beta induces IgA production and acts additively with interleukin 5 for IgA production. J. Exptl. Med. 1989; 170: 1415–1420, [CROSSREF]
- Staats H. F., Jackson R. J., Marinaro M., et al. Mucosal immunity to infection with implications for vaccine development. Curr. Opin. Immun. 1994; 6: 572–583, [CROSSREF], [CSA]
- Steinmertz I. Comparative in vivo analysis of IgA- and IgG-mediated mucosal defense against bacterial pathogens. Behring Inst. Mitt. 1997; 98: 53–55
- Toumanen E. I., Austrian R., Masure H. R. Pathogenesis of pneumococcal infection. N. Eng. J. Med. 1995; 11: 1280–1284, [CROSSREF]
- Unkeless J. C., Selgliano E., Freedman V. H. Structure and function of human and murine receptors for TgG. Annu. Rev. Immunol. 1988; 6: 251–281, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Verweij W. R., de Haan L., Holtrop M., et al. Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: Induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenzae virus surface antigen. Vaccine 1998; 16: 2069–2076, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Vidarsson G., Jonsdottir G., Jonsson S., et al. Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae. J. Infect. Dis. 1994; 170: 592–599
- Von Hunolstein C., Mariotti S., Teloni R., et al. The adjuvant effect of synthetic oligodeoxynucleotide containing CpG motif converts the anti-Haemophilus influenzae type b glycoconjugates into efficient anti-polysaccharide and anti-carrier polyvalent vaccines. Vaccine 2001; 19: 3058–3066, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Watson D. A., Musher D. M., Verhoef J. Pneumococcal virulence factors and host immune responses to them. Eur. J. Clin. Microbiol. Infect. Dis. 1995; 14: 479–490, [PUBMED], [INFOTRIEVE], [CSA]
- Weeratna R. D., McCluskie M. J., Xu Y., et al. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 2000; 18: 1755–1762, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]